What is Emulate?
Headquartered in Boston, Massachusetts, and established in 2013, Emulate is at the forefront of the Organs-on-Chips industry. The company specializes in recreating organ-level functions using human cell-based technology, providing a sophisticated alternative to traditional animal testing. By modeling both healthy and diseased states, Emulate enables pharmaceutical and biotech researchers to gain deeper insights into human biology, thereby accelerating the development of safer and more effective therapeutic interventions. Their market position is defined by high-barrier technical innovation and a focus on complex, highly regulated life science environments.
How much funding has Emulate raised?
Emulate has raised a total of $169M across 7 funding rounds:
Series A
$12M
Series B
$17M
Grant
$2M
Private Equity
$745K
Series C
$36M
Other Financing Round
$19.3M
Series E
$82M
Series A (2014): $12M with participation from NanoDimension and Cedars-Sinai
Series B (2016): $17M led by NanoDimension, ATEL Capital Group, ALS Finding a Cure, Cedars-Sinai, OS Fund, and Laboratory Corporation of Americau00ae Holdings
Grant (2017): $2M supported by National Center for Advancing Translational Sciences
Private Equity (2017): $745K, investors not publicly disclosed
Series C (2018): $36M backed by ALS Investment Fund, Starlight Ventures, Founders Fund, and SciFi VC
Other Financing Round (2020): $19.3M with participation from NanoDimension, Blue Ivy Ventures, ALSInvestment Fund, Founders Fund LLC, Cedars-Sinai, and Northpond Ventures LLC
Series E (2021): $82M led by Northpond Ventures and Perceptive Advisors
Key Investors in Emulate
Founders Fund
A venture capital firm that invests in transformative companies across all stages, known for backing industry-defining organizations like SpaceX and Palantir.
Perceptive Advisors
An investment firm managing significant assets with a specialized focus on funding innovative healthcare and life sciences technologies.
NanoDimension
A venture capital firm established in 2002 that focuses on investing in disruptive technologies across life, physical, and data sciences.
What's next for Emulate?
Following the recent infusion of capital, Emulate is well-positioned to scale its commercial operations and expand its research capabilities. The company is expected to leverage this financial backing to deepen its partnerships with global pharmaceutical entities and further validate its platform across diverse therapeutic areas. As the firm transitions into its next phase of maturity, the focus will likely shift toward broader clinical adoption and the integration of its technology into standard drug development workflows, solidifying its role as a critical infrastructure provider in the modern biomedical landscape.
See full Emulate company page
